Aardvark Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$49M
D&A
$36K
Operating Income
$-63M
EBITDA
$-63M
Tax Provision
$0
Net Income
$-58M
Operating Margin
-943.9%
Net Margin
-852.9%
DTA Valuation Allowance
$39M
NOL Carryforwards
$23M
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.2%
Operating Lease Cost
$900K
Revenue YoY Variation
-100.0%
Income YoY Variation
-175.3%